Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

ed monthly and reviewed by the Company's

management and are presented quarterly to the Board.

Historically, funding for the Company's plan is primarily managed through

the issuance of additional common shares and common share purchase

warrants that upon exercise are converted to common shares. Management

regularly monitors the capital markets attempting to balance the timing

of issuing additional equity with the Company's progress through its

clinical trial program, general market conditions, and the availability

of capital. There are no assurances that funds will be made available to

the Company when required.

The Company is not subject to externally imposed capital requirements.

7. SHORT-TERM INVESTMENTS

Short-term investments, consisting of bankers' acceptances, are liquid

investments that are readily convertible to known amounts of cash and are

subject to an insignificant risk of changes in value. The objectives for

holding short-term investments are to invest the Company's excess cash

resources in investment vehicles that provide a better rate of return

compared to the Company's interest bearing bank account with limited risk

to the principal invested. The Company also intends to match the

maturities of these short-term investments with the cash requirements of

the Company's activities. The Company does not hold any asset backed

commercial paper.

Effective

Original Accrued Carrying Fair Interest

Cost Interest Value Value Rate

$ $ $ $

-------------------------------------------------------------------------

March 31, 2008

Short-term

investments 14,576,744 59,176 14,635,920 14,539,205 2
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. (NASDAQ: ... and marketer of patent protected regenerative biomaterials and ... publication of another peer-reviewed clinical study.    ... Multi-center Randomized Controlled Clinical Trial Evaluating the Use ... Allografts and Multi-layer Compression Therapy vs. Multi-layer Compression ...
(Date:9/17/2014)... 17, 2014 Immunomic Therapeutics, Inc. announced ... (SBIR) grant to support the continued preclinical development of ... with approximately $255,000 over one year to conduct vaccine ... food allergy, affect over one million Americans and are ... Tree nut exposure is also a risk for peanut ...
(Date:9/17/2014)... Alternative Fuels Americas, Inc. (AFAI) announced today that ... Vehicle in partnership with Jatro Greentech, Inc., a ... SPV shall be called AFAI Jatro Green Ethiopia and will ... The SPV shall pursue Jatropha planting and biofuels production projects ... . "Although we have experienced great ...
(Date:9/17/2014)... , 17 de septiembre de 2014 ... compañía"), principal proveedor mundial de soluciones logísticas ... ciencias de la vida, anunció hoy la ... logística global con sede en Rótterdam, Países ... de clientes Europa en rápido crecimiento. Según ...
Breaking Biology Technology:MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5
... ... sectors suffer, savvy investors like Prudential target healthcare , ... Minneapolis (Vocus) – Even as other commercial real ... healthcare real estate. Recent deals have included $250 million in new debt and $30 ...
... , BETHESDA, Md., July 30 Micromet, Inc. ... proprietary antibodies for the treatment of cancer, inflammation and autoimmune ... 14,000,000 shares of its common stock at a public offering ... are being offered by Micromet. The gross proceeds to ...
... , , , ... CRTX ), a specialty pharmaceutical company focused ... the respiratory and related markets, today announced that it ... a leading European pharmaceutical company headquartered in Parma, Italy. ...
Cached Biology Technology:Millions Flowing into Medical Real Estate 2Millions Flowing into Medical Real Estate 3Micromet Announces Pricing of Public Offering of Common Stock 2Micromet Announces Pricing of Public Offering of Common Stock 3Micromet Announces Pricing of Public Offering of Common Stock 4Cornerstone Therapeutics Announces Closing of Chiesi Transaction 2Cornerstone Therapeutics Announces Closing of Chiesi Transaction 3Cornerstone Therapeutics Announces Closing of Chiesi Transaction 4Cornerstone Therapeutics Announces Closing of Chiesi Transaction 5Cornerstone Therapeutics Announces Closing of Chiesi Transaction 6
(Date:9/16/2014)... 2014)More than $100 trillion in cumulative public and ... dioxide (CO2)a 40 percent reduction of urban passenger ... world expands public transportation, walking and cycling in ... the University of California, Davis, and the Institute ... Further, an estimated 1.4 million early deaths could ...
(Date:9/16/2014)... The fire is human-caused and is still under ... and is mostly being fueled by grass and timber. ... to higher humidity. Yesterday (8/15), firefighters made progress ... fireline on the West and North sides of the fire. ... 7 20-person Crews, 4 Hot Shot Crews, 1 large Type ...
(Date:9/16/2014)... take up residence in and on the human body ... according to new research at Washington University School of ... individuals carry about five types of viruses on their ... Biology . The study is the first comprehensive analysis ... , The research was conducted as part of ...
Breaking Biology News(10 mins):Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3
... , This release is available in Spanish . ... Agriculture (USDA) scientists working as part of an international team have ... in the journal Nature reported today. The achievement ... speed up development of wheat varieties with enhanced nutritional value. ...
... part of their ongoing research on the role of ... Diabetes Center scientists, in collaboration with scientists at the ... associated with type 1 diabetes and other autoimmune diseases ... upcoming issue of Diabetes . Recent studies ...
... aestivum ) is one of the "big three" globally important ... Fully 35% of the world,s 7 billion people depend on ... scientists, including a group from Cold Spring Harbor Laboratory (CSHL), ... The study reveals the evolution of bread wheat ...
Cached Biology News:USDA scientists and cooperators sequence the wheat genome in breakthrough for global food security 2USDA scientists and cooperators sequence the wheat genome in breakthrough for global food security 3Joslin researchers increase understanding of genetic risk factor for type 1 diabetes 2Bread wheat's large and complex genome is revealed 2Bread wheat's large and complex genome is revealed 3
... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
... Purity is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has ... of new radiolabeled ligands selected to keep ... wide range of products and services for ... 400 state-of-the-art radioligands. If you do not ...
... The Fluorescence Test Plate consists of an ... with Inert Organic Fluorescent Compounds embedded in ... used on BioTeks FLx800 and Synergy Multi-Detection ... for GLP compliance while reducing the need ...
... Feature Extraction Software reads and ... to prepare microarray data for ... * one 2-year license ... NFP/Academic accounts , * ...
Biology Products: